Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Symic Biomedical
953 Indiana Street
San Francisco, CA 94107
Phone: 415-805-9005
www.symicbio.com

Symic Biomedical is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. Symic's compounds function like proteoglycans, important structural and functional macromolecules native to the ECM (extracellular matrix). The ECM is the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, play a critical role in maintaining tissue function and healing upon injury or in chronic diseases - Symic's molecules function in a similar manner. Symic is targeting the ECM using its proprietary and novel proteoglycan mimics, and will advance its compounds in a variety of acute and chronic therapeutic areas with significant unmet clinical needs.

Key Contact
Name
Ken Horne
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
01/06/15 $15,000,000 Series A Ally Bridge Group
Den Danske Forskningsfond
InCube Ventures
Lilly Ventures
Mission Bay Capital
Mitsui Global Investment
Purdue Foundry Investment Fund
QB3
undisclosed